Efficacy and ligand bias at the μ-opioid receptor

British Journal of Pharmacology

Volumn 169, Issue 7, 2013, Pages 1430-1446

  Kelly, E ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

opioid receptor; efficacy; GPCR; intrinsic efficacy; ligand bias

Indexed keywords

BETA FUNALTREXAMINE; BUPRENORPHINE; CHLORNALTREXAMINE; CLOCINNAMOX; ENDORPHIN; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; G PROTEIN COUPLED RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; LIGAND; MORPHINE; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR AGONIST; PENTAZOCINE; PETHIDINE; RETINA S ANTIGEN;

ANALGESIC ACTIVITY; CANCER PAIN; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; HUMAN; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR INTRINSIC ACTIVITY; RESPIRATION DEPRESSION; REVIEW; SIGNAL TRANSDUCTION;

Μ-OPIOID RECEPTOR; EFFICACY; GPCR; INTRINSIC EFFICACY; LIGAND BIAS;

ANALGESICS, OPIOID; ANIMALS; ENKEPHALIN, ALA(2)-MEPHE(4)-GLY(5)-; HUMANS; MORPHINE; RECEPTORS, OPIOID, MU;

EID: 84880311864     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12222     Document Type: Review

References (99)

1. Alexander SP, Mathie A, Peters JA, (2011). Guide to Receptors and Channels (GRAC), 5th edition. Br J Pharmacol 164 (Suppl. 1): S1-S324.
2. Bailey CP, Llorente J, Gabra BH, Smith FL, Dewey WL, Kelly E, et al. (2009). Role of protein kinase C and mu-opioid receptor (MOP receptor) desensitization in tolerance to morphine in rat locus coeruleus neurons. Eur J Neurosci 29: 307-318.
3. Bassoni DL, Raab WJ, Achacoso PL, Loh CY, Wehrman TS, (2012). Measurements of β-arrestin recruitment to activated seven transmembrane receptors using enzyme complementation. Methods Mol Biol 897: 181-203.
4. Bennett MI, Graham J, Schmidt-Hansen M, Prettyjohns M, Arnold S, Group GD, (2012). Prescribing strong opioids for pain in adult palliative care: summary of NICE guidance. BMJ 344: e2806.
5. Black JW, Leff P, (1983). Operational models of pharmacological agonism. Proc R Soc Lond B Biol Sci 220: 141-162.
6. Bohn L, Lefkowitz R, Gainetdinov R, Peppel K, Caron M, Lin F, (1999). Enhanced morphine analgesia in mice lacking beta-arrestin 2. Science 286: 2495-2498.
7. Borgland S, Connor M, Osborne P, Furness J, Christie M, (2003). Opioid agonists have different efficacy profiles for G protein activation, rapid desensitization, and endocytosis of mu-opioid receptors. J Biol Chem 278: 18776-18784.
8. Chan K, Brodsky M, Davis T, Franklin S, Inturrisi CE, Yoburn BC, (1995). The effect of the irreversible mu-opioid receptor antagonist clocinnamox on morphine potency, receptor binding and receptor mRNA. Eur J Pharmacol 287: 135-143.
9. Chavkin C, Goldstein A, (1982). Reduction in opiate receptor reserve in morphine tolerant guinea pig ilea. Life Sci 31: 1687-1690.
10. Chavkin C, Goldstein A, (1984). Opioid receptor reserve in normal and morphine-tolerant guinea pig ileum myenteric plexus. Proc Natl Acad Sci U S A 81: 7253-7257.
11. Christie MJ, Williams JT, North RA, (1987). Cellular mechanisms of opioid tolerance: studies in single brain neurons. Mol Pharmacol 32: 633-638.
12. Christopoulos A, El-Fakahany EE, (1999). Qualitative and quantitative assessment of relative agonist efficacy. Biochem Pharmacol 58: 735-748.
13. Clarke WP, Berg KA, (2010). Use of functional assays to detect and quantify functional selectivity. Drug Discov Today 7: e31-e36.
14. Clarke WP, Bond RA, (1998). The elusive nature of intrinsic efficacy. Trends Pharmacol Sci 19: 270-276.
15. Colquhoun D, (1998). Binding, gating, affinity and efficacy: the interpretation of structure-activity relationships for agonists and of the effects of mutating receptors. Br J Pharmacol 125: 924-947.
16. Cox EH, Kerbusch T, Van der Graaf PH, Danhof M, (1998). Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the mu-opioid receptor. J Pharmacol Exp Ther 284: 1095-1103.
17. Dahan A, Yassen A, Bijl H, Romberg R, Sarton E, Teppema L, et al. (2005). Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats. Br J Anaesth 94: 825-834.
18. Dang VC, Chieng B, Azriel Y, Christie MJ, (2011). Cellular morphine tolerance produced by βarrestin-2-dependent impairment of μ-opioid receptor resensitization. J Neurosci 31: 7122-7130.
19. Dewire SM, Yamashita DS, Rominger DH, Liu G, Cowan CL, Graczyk TM, et al. (2013). A G protein-biased ligand at the μ-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine. J Pharmacol Exp Ther 344: 708-717.
20. Doll C, Pöll F, Peuker K, Loktev A, Glück L, Schulz S, (2012). Deciphering μ-opioid receptor phosphorylation and dephosphorylation in HEK293 cells. Br J Pharmacol 167: 1259-1270.
21. Ehlert FJ, (1985). The relationship between muscarinic receptor occupancy and adenylate cyclase inhibition in the rabbit myocardium. Mol Pharmacol 28: 410-421.
22. Ehlert FJ, (2008). On the analysis of ligand-directed signaling at G protein-coupled receptors. Naunyn Schmiedebergs Arch Pharmacol 377: 549-577.
23. Ehlert FJ, Griffin MT, Suga H, (2011). Analysis of functional responses at G protein-coupled receptors: estimation of relative affinity constants for the inactive receptor state. J Pharmacol Exp Ther 338: 658-670.
24. Emmerson PJ, Clark MJ, Mansour A, Akil H, Woods JH, Medzihradsky F, (1996). Characterization of opioid agonist efficacy in a C6 glioma cell line expressing the mu opioid receptor. J Pharmacol Exp Ther 278: 1121-1127.
25. Evans BA, Broxton N, Merlin J, Sato M, Hutchinson DS, Christopoulos A, et al. (2011). Quantification of functional selectivity at the human α(1A)-adrenoceptor. Mol Pharmacol 79: 298-307.
26. Figueroa KW, Griffin MT, Ehlert FJ, (2009). Selectivity of agonists for the active state of M1 to M4 muscarinic receptor subtypes. J Pharmacol Exp Ther 328: 331-342.
27. Frölich N, Dees C, Paetz C, Ren X, Lohse MJ, Nikolaev VO, et al. (2011). Distinct pharmacological properties of morphine metabolites at G(i)-protein and β-arrestin signaling pathways activated by the human μ-opioid receptor. Biochem Pharmacol 81: 1248-1254.
28. Furchgott RF, Bursztyn P, (1967). Comparison of dissociation constants and of relative efficacies of selected agonists acting on parasympathetic receptors. Ann NY Acad Sci 144: 882-898.
29. Garrido M, Gubbens-Stibbe J, Tukker E, Cox E, von Frijtag J, Künzel D, et al. (2000). Pharmacokinetic-pharmacodynamic analysis of the EEG effect of alfentanil in rats following beta-funaltrexamine-induced mu-opioid receptor 'knockdown' in vivo. Pharm Res 17: 653-659.
30. Griffin MT, Figueroa KW, Liller S, Ehlert FJ, (2007). Estimation of agonist activity at G protein-coupled receptors: analysis of M2 muscarinic receptor signaling through Gi/o,Gs, and G15. J Pharmacol Exp Ther 321: 1193-1207.
31. Groer CE, Tidgewell K, Moyer RA, Harding WW, Rothman RB, Prisinzano TE, et al. (2007). An opioid agonist that does not induce mu-opioid receptor-arrestin interactions or receptor internalization. Mol Pharmacol 71: 549-557.
32. Groer CE, Schmid CL, Jaeger AM, Bohn LM, (2011). Agonist-directed interactions with specific beta-arrestins determine mu-opioid receptor trafficking, ubiquitination, and dephosphorylation. J Biol Chem 286: 31731-31741.
33. Haberstock-Debic H, Wein M, Barrot M, Colago EE, Rahman Z, Neve RL, et al. (2003). Morphine acutely regulates opioid receptor trafficking selectively in dendrites of nucleus accumbens neurons. J Neurosci 23: 4324-4332.
34. Haberstock-Debic H, Kim KA, Yu YJ, von Zastrow M, (2005). Morphine promotes rapid, arrestin-dependent endocytosis of mu-opioid receptors in striatal neurons. J Neurosci 25: 7847-7857.
35. Hall DA, Langmead CJ, (2010). Matching models to data: a receptor pharmacologist's guide. Br J Pharmacol 161: 1276-1290.
36. Hanks GW, Conno F, Cherny N, Hanna M, Kalso E, McQuay HJ, et al. (2001). Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 84: 587-593.
37. Henry AG, Hislop JN, Grove J, Thorn K, Marsh M, von Zastrow M, (2012). Regulation of endocytic clathrin dynamics by cargo ubiquitination. Dev Cell 23: 519-532.
38. Hull LC, Llorente J, Gabra BH, Smith FL, Kelly E, Bailey C, et al. (2010). The effect of protein kinase C and G protein-coupled receptor kinase inhibition on tolerance induced by mu-opioid agonists of different efficacy. J Pharmacol Exp Ther 332: 1127-1135.
39. Ishii K, Yamamoto S, Muraki T, Kato R, (1981). Partial agonistic action of morphine in the rat vas deferens. Jpn J Pharmacol 31: 905-909.
40. January B, Seibold A, Whaley B, Hipkin RW, Lin D, Schonbrunn A, et al. (1997). beta2-adrenergic receptor desensitization, internalization, and phosphorylation in response to full and partial agonists. J Biol Chem 272: 23871-23879.
41. Just S, Illing S, Trester-Zedlitz M, Lau EK, Kotowski SJ, Miess E, et al. (2013). Differentiation of opioid drug effects by hierarchical multi-site phosphorylation. Mol Pharmacol 83: 633-639.
42. Kahsai AW, Xiao K, Rajagopal S, Ahn S, Shukla AK, Sun J, et al. (2011). Multiple ligand-specific conformations of the β2-adrenergic receptor. Nat Chem Biol 7: 692-700.
43. Kang M, Maguma HT, Smith TH, Ross GR, Dewey WL, Akbarali HI, (2012). The role of β-arrestin2 in the mechanism of morphine tolerance in the mouse and guinea pig gastrointestinal tract. J Pharmacol Exp Ther 340: 567-576.
44. Kelly E, Bailey CP, Henderson G, (2008). Agonist-selective mechanisms of GPCR desensitization. Br J Pharmacol 153 (Suppl. 1): S379-S388.
45. Kenakin T, (2013). New concepts in pharmacological efficacy at 7TM receptors. Br J Pharmacol 168: 554-575.
46. Kenakin T, Christopoulos A, (2013). Signalling bias in new drug discovery: detection, quantification and therapeutic impact. Nat Rev Drug Discov 12: 205-216.
47. Kenakin T, Watson C, Muniz-Medina V, Christopoulos A, Novick S, (2012). A simple method for quantifying functional selectivity and agonist bias. ACS Chem Neurosci 3: 193-203.
48. Kilpatrick LE, Holliday ND, (2012). Dissecting the pharmacology of G protein-coupled receptor signaling complexes using bimolecular fluorescence complementation. Methods Mol Biol 897: 109-138.
49. Kim HK, Smiddy M, Hoffman RS, Nelson LS, (2012). Buprenorphine may not be as safe as you think: a pediatric fatality from unintentional exposure. Pediatrics 130: e1700-e1703.
50. Lamb K, Tidgewell K, Simpson DS, Bohn LM, Prisinzano TE, (2012). Antinociceptive effects of herkinorin, a MOP receptor agonist derived from salvinorin A in the formalin test in rats: new concepts in mu opioid receptor pharmacology: from a symposium on new concepts in mu-opioid pharmacology. Drug Alcohol Depend 121: 181-188.
51. Langemeijer EV, Verzijl D, Dekker SJ, Ijzerman AP, (2013). Functional selectivity of adenosine A(1) receptor ligands? Purinergic Signal 9: 91-100.
52. Lau EK, Trester-Zedlitz M, Trinidad JC, Kotowski SJ, Krutchinsky AN, Burlingame AL, et al. (2011). Quantitative encoding of the effect of a partial agonist on individual opioid receptors by multisite phosphorylation and threshold detection. Sci Signal 4: ra52.
53. Luttrell LM, Gesty-Palmer D, (2010). Beyond desensitization: physiological relevance of arrestin-dependent signaling. Pharmacol Rev 62: 305-330.
54. McConalogue K, Grady EF, Minnis J, Balestra B, Tonini M, Brecha NC, et al. (1999). Activation and internalization of the mu-opioid receptor by the newly discovered endogenous agonists, endomorphin-1 and endomorphin-2. Neuroscience 90: 1051-1059.
55. McPherson J, Rivero G, Baptist M, Llorente J, Al-Sabah S, Krasel C, et al. (2010). μ-Opioid receptors: correlation of agonist efficacy for signalling with ability to activate internalization. Mol Pharmacol 78: 756-766.
56. McQuay H, (1999). Opioids in pain management. Lancet 353: 2229-2232.
57. Madia PA, Dighe SV, Sirohi S, Walker EA, Yoburn BC, (2009). Dosing protocol and analgesic efficacy determine opioid tolerance in the mouse. Psychopharmacol 207: 413-422.
58. Madia PA, Navani DM, Yoburn BC, (2012). [(35)S]GTPγS binding and opioid tolerance and efficacy in mouse spinal cord. Pharmacol Biochem Behav 101: 155-165.
59. Mégarbane B, Hreiche R, Pirnay S, Marie N, Baud FJ, (2006). Does high-dose buprenorphine cause respiratory depression?: possible mechanisms and therapeutic consequences. Toxicol Rev 25: 79-85.
60. Mjanger E, Yaksh TL, (1991). Characteristics of dose-dependent antagonism by beta-funaltrexamine of the antinociceptive effects of intrathecal mu agonists. J Pharmacol Exp Ther 258: 544-550.
61. Mittal N, Tan M, Egbuta O, Desai N, Crawford C, Xie CW, et al. (2012). Evidence that behavioral phenotypes of morphine in β-arr2-/- mice are due to the unmasking of JNK signaling. Neuropharmacol 37: 1953-1962.
62. Molinari P, Vezzi V, Sbraccia M, Grò C, Riitano D, Ambrosio C, et al. (2010). Morphine-like opiates selectively antagonize receptor-arrestin interactions. J Biol Chem 285: 12522-12535.
63. Morgan MM, Christie MJ, (2011). Analysis of opioid efficacy, tolerance, addiction and dependence from cell culture to human. Br J Pharmacol 164: 1322-1334.
64. Navratilova E, Waite S, Stropova D, Eaton MC, Alves ID, Hruby VJ, et al. (2007). Quantitative evaluation of human delta opioid receptor desensitization using the operational model of drug action. Mol Pharmacol 71: 1416-1426.
65. Nickerson M, (1956). Receptor occupancy and tissue response. Nature 178: 697-698.
66. Nickolls SA, Waterfield A, Williams RE, Kinloch RA, (2011). Understanding the effect of different assay formats on agonist parameters: a study using the μ-opioid receptor. J Biomol Screen 16: 706-716.
67. Nijmeijer S, Vischer HF, Rosethorne EM, Charlton SJ, Leurs R, (2012). Analysis of multiple Histamine H4 receptor compound classes uncovers Gαi protein- and β-Arrestin2-biased ligands. Mol Pharmacol 82: 1174-1182.
68. Osborne PB, Williams JT, (1995). Characterization of acute homologous desensitization of mu-opioid receptor-induced currents in locus coeruleus neurones. Br J Pharmacol 115: 925-932.
69. Psigfogeorgou K, Terzi D, Papachatzaki MM, Varidaki A, Ferguson D, Gold SJ, et al. (2011). A unique role of RGS9-2 in the striatum as a positive or negative regulator of opiate analgesia. J Neurosci 31: 5617-5624.
70. Quillinan N, Lau EK, Virk M, von Zastrow M, Williams JT, (2011). Recovery from mu-opioid receptor desensitization after chronic treatment with morphine and methadone. J Neurosci 31: 4434-4443.
71. Raehal KM, Walker JK, Bohn LM, (2005). Morphine side effects in beta-arrestin 2 knockout mice. J Pharmacol Exp Ther 314: 1195-1201.
72. Raehal KM, Schmid CL, Groer CE, Bohn LM, (2011). Functional selectivity at the μ-opioid receptor: implications for understanding opioid analgesia and tolerance. Pharmacol Rev 63: 1001-1019.
73. Rajagopal S, Rajagopal K, Lefkowitz RJ, (2010). Teaching old receptors new tricks: biasing seven-transmembrane receptors. Nat Rev Drug Discov 9: 373-386.
74. Rajagopal S, Ahn S, Rominger DH, Gowen-MacDonald W, Lam CM, Dewire SM, et al. (2011). Quantifying ligand bias at seven-transmembrane receptors. Mol Pharmacol 80: 367-377.
75. Rivero G, Llorente J, McPherson J, Cooke A, Mundell SJ, McArdle CA, et al. (2012). Endomorphin-2: a biased agonist at the μ-opioid receptor. Mol Pharmacol 82: 178-188.
76. Rõnai AZ, Al-Khrasani M, Benyhe S, Lengyel I, Kocsis L, Orosz G, et al. (2006). Partial and full agonism in endomorphin derivatives: comparison by null and operational model. Peptides 27: 1507-1513.
77. Ruffolo RR, (1982). Review important concepts of receptor theory. J Auton Pharmacol 2: 277-295.
78. Schulz S, Mayer D, Pfeiffer M, Stumm R, Koch T, Höllt V, (2004). Morphine induces terminal micro-opioid receptor desensitization by sustained phosphorylation of serine-375. EMBO J 23: 3282-3289.
79. Selley DE, Sim LJ, Xiao R, Liu Q, Childers SR, (1997). mu-Opioid receptor-stimulated guanosine-5′-O-(gamma-thio)-triphosphate binding in rat thalamus and cultured cell lines: signal transduction mechanisms underlying agonist efficacy. Mol Pharmacol 51: 87-96.
80. Selley DE, Liu Q, Childers SR, (1998). Signal transduction correlates of mu opioid agonist intrinsic efficacy: receptor-stimulated [35S]GTP gamma S binding in mMOR-CHO cells and rat thalamus. J Pharmacol Exp Ther 285: 496-505.
81. Sim LJ, Liu Q, Childers SR, Selley DE, (1998). Endomorphin-stimulated [35S]GTPgammaS binding in rat brain: evidence for partial agonist activity at mu-opioid receptors. J Neurochem 70: 1567-1576.
82. Smith CF, Rance MJ, (1983). Opiate receptors in the rat vas deferens. Life Sci 33: 327-330.
83. Stallaert W, Christopoulos A, Bouvier M, (2011). Ligand functional selectivity and quantitative pharmacology at G protein-coupled receptors. Expert Opin Drug Discov 6: 811-825.
84. Stephenson RP, (1956). A modification of receptor theory. Br J Pharmacol Chemother 11: 379-393.
85. Strange PG, (2008). Agonist binding, agonist affinity and agonist efficacy at G protein-coupled receptors. Br J Pharmacol 153: 1353-1363.
86. Traynor J, (2012). μ-Opioid receptors and regulators of G protein signaling (RGS) proteins: from a symposium on new concepts in mu-opioid pharmacology. Drug Alcohol Depend 121: 173-180.
87. Trescot AM, Datta S, Lee M, Hansen H, (2008). Opioid pharmacology. Pain Physician 11: S133-S153.
88. Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, et al. (2007). Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 320: 1-13.
89. Varamini P, Mansfeld FM, Blanchfield JT, Wyse BD, Smith MT, Toth I, (2012). Lipo-endomorphin-1 derivatives with systemic activity against neuropathic pain without producing constipation. PLoS One 7: e41909.
90. Wacker D, Wang C, Katritch V, Han GW, Huang XP, Vardy E, et al. (2013). Structural features for functional selectivity at serotonin receptors. Science 340: 615-619.
91. Walwyn W, Evans CJ, Hales TG, (2007). Beta-arrestin2 and c-Src regulate the constitutive activity and recycling of mu opioid receptors in dorsal root ganglion neurons. J Neurosci 27: 5092-5104.
92. Whalen EJ, Rajagopal S, Lefkowitz RJ, (2011). Therapeutic potential of β-arrestin- and G protein-biased agonists. Trends Mol Med 17: 126-139.
93. Whistler JL, Chuang HH, Chu P, Jan LY, von Zastrow M, (1999). Functional dissociation of mu opioid receptor signaling and endocytosis: implications for the biology of opiate tolerance and addiction. Neuron 23: 737-746.
94. Williams JT, North RA, (1984). Opiate-receptor interactions on single locus coeruleus neurones. Mol Pharmacol 26: 489-497.
95. Wilson AM, Soignier RD, Zadina JE, Kastin AJ, Nores WL, Olson RD, et al. (2000). Dissociation of analgesic and rewarding effects of endomorphin-1 in rats. Peptides 21: 1871-1874.
96. Zadina JE, Hackler L, Ge LJ, Kastin AJ, (1997). A potent and selective endogenous agonist for the mu-opiate receptor. Nature 386: 499-502.
97. Zaki PA, Keith DE, Brine GA, Carroll FI, Evans CJ, (2000). Ligand-induced changes in surface mu-opioid receptor number: relationship to G protein activation? J Pharmacol Exp Ther 292: 1127-1134.
98. Zhang J, Ferguson SS, Barak LS, Bodduluri SR, Laporte SA, Law PY, et al. (1998). Role for G protein-coupled receptor kinase in agonist-specific regulation of mu-opioid receptor responsiveness. Proc Natl Acad Sci U S A 95: 7157-7162.
99. Zheng H, Loh HH, Law PY, (2008). Beta-arrestin-dependent mu-opioid receptor-activated extracellular signal-regulated kinases (ERKs) translocate to nucleus in contrast to G protein-dependent ERK activation. Mol Pharmacol 73: 178-190.